-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Dyne Therapeutics, Maintains $38 Price Target

Benzinga·03/09/2026 18:13:25
Listen to the news
Chardan Capital analyst Keay Nakae maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and maintains $38 price target.